<PAGE>
- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO
SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): APRIL 18, 2000
--------------------
GENOME THERAPEUTICS CORP.
(Exact name of registrant as specified in its charter)
MASSACHUSETTS 0-10824 04-2297484
(State or other jurisdiction (Commission File Number) (I.R.S. Employer
of incorporation) Identification Number)
100 BEAVER STREET
WALTHAM, MASSACHUSETTS 02453
(Address, of principal executive offices, including zip code)
(781) 398-2300
(Registrant's Telephone number including area code)
--------------------
- --------------------------------------------------------------------------------
<PAGE>
Item 5. OTHER EVENTS
On April 13, 2000, Genome Therapeutics Corp. issued a press release
announcing that it would not proceed with its follow-on public offering and
that it would file an amendment to the registration statement that it filed
with the Securities and Exchange Commission on March 16, 2000 to convert it
to a shelf registration statement. A copy of this press release is attached
to this Current Report on Form 8-K as Exhibit 99.1.
-2-
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GENOME THERAPEUTICS CORP.
By /s/ Robert J. Hennessey
---------------------------------
Title: Chairman of the Board and
Chief Executive Officer
Date: April 18, 2000
-3-
<PAGE>
EXHIBIT INDEX
99.1 Press Release dated April 13, 2000
-4-
<PAGE>
Contacts:
Christopher Taylor Douglas MacDougall
Director of Investor Relations Vice President
Genome Therapeutics Corp. Feinstein Kean Healthcare
781.398.2466 617.577.8110
FOR IMMEDIATE RELEASE
GENOME THERAPEUTICS CANCELS FOLLOW-ON PUBLIC OFFERING
WALTHAM, MASS., APRIL 13, 2000 -- Genome Therapeutics Corp. (Nasdaq: GENE)
announced that in light of recent market volatility and current market
conditions, the Company would not proceed with its proposed follow-on public
offering at this time. Genome Therapeutics will file an amendment to the
registration statement that it filed with the Securities and Exchange Commission
on March 16, 2000 to convert it to a shelf registration statement.
Genome Therapeutics (WWW.GENOMECORP.COM) is a leader in the commercialization of
genomics-based drug discovery. The Company's gene discovery strategy is to
identify and characterize human genes associated with major diseases and
elucidate microbial genes as novel drug targets against many serious infectious
organisms. Together with its strategic partners, including Schering-Plough,
AstraZeneca, Wyeth-Ayerst and bioMerieux, Genome Therapeutics is using genomic
information to develop a new generation of genomics-based pharmaceutical,
vaccine and diagnostic products.
# # #
